US FDA Picks Up The Pace Of Complete Response Letters Over June And July
The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.
The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.